IP Library › Granted Patent US 8,026,216
Granted Patent B2
US 8,026,216 · App. 12/101,008 · Granted Sep 27, 2011

Methods and compositions for contributing to the treatment of cancers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,026,216
App. No.
12/101,008
Granted
Sep 27, 2011
Kind
B2
Abstract

Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ET B ) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).

Claims (12)

1. A method of contributing to the treatment of cancer comprising administering an endothelin B (ETB) receptor agonist and a chemotherapeutic agent;

wherein said ETB receptor agonist consists of IRL 1620, and wherein said cancer is an ovarian tumor.

2. The method according to claim 1 , wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, camptothecin, carboplatin, cisplatin, cyclophosphamide, daunorubicin, alpha interferon, beta interferon, gamma interferon, interleukin 2, irinotecan, docetaxel, paclitaxel, topotecan, 5-fluorouracil, and combinations thereof.

3. The method according to claim 1 , wherein said IRL-1620 and said chemotherapeutic agent are administered substantially simultaneously.

4. The method according to claim 3 , wherein said IRL-1620 and said chemotherapeutic agent are administered as a single composition.

5. The method according to claim 1 , wherein said IRL-1620 and said chemotherapeutic agent are administered sequentially.

6. The method according to claim 5 , wherein said chemotherapeutic agent is administered prior to said IRL-1620.

7. The method according to claim 5 , wherein said IRL-1620 is administered prior to said chemotherapeutic agent.

8. A composition comprising at least one chemotherapeutic agent, IRL-1620, and an optional excipient.

9. The composition according to claim 8 , wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, camptothecin, carboplatin, cisplatin, cyclophosphamide, daunorubicin, alpha interferon, beta interferon, gamma interferon, interleukin 2, irinotecan, docetaxel, paclitaxel, topotecan, 5-fluorouracil, and combinations thereof.

10. The composition according to claim 8 , wherein said chemotherapeutic agent is cisplatin, cyclophosphamide, or a combination thereof.

11. The composition according to claim 8 , wherein said chemotherapeutic agent is paclitaxel.

Assignments (4)
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT RECORDED AT REEL 061179/FRAME 0202 Recorded Aug 1, 2023
From: SLR INVESTMENT CORP.
To: SPECTRUM PHARMACEUTICALS, INC.; ALLOS THERAPEUTICS, INC.; TALON THERAPEUTICS, INC.
Reel/Frame 064463/0709 →
SECURITY INTEREST Recorded Sep 22, 2022
From: SPECTRUM PHARMACEUTICALS, INC.; ALLOS THERAPEUTICS, INC.; TALON THERAPEUTICS, INC.
To: SLR INVESTMENT CORP., AS COLLATERAL AGENT
Reel/Frame 061179/0202 →
RELEASE OF SECURITY INTEREST Recorded Jan 17, 2014
From: BANK OF AMERICA, N.A.
To: SPECTRUM PHARMACEUTICALS, INC.
Reel/Frame 031995/0892 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 20, 2012
From: SPECTRUM PHARMACEUTICALS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 029017/0877 →